STAT+: Stealth biotech Stipple bets on secretive ADCs
Source ↗
👁 27
💬 0
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
A four-month FDA delay prompted a cash-strapped biotech company to shutter. The White House’s proposed NIH cuts are drawing bipartisan backlash. Peptide hype is outpacing evidence. And more!
The need-to-know this morning
Neurocrine Biosciences said this morning that it would buy Soleno Therapeutics and its treatment for Prader-Willi syndrome
A four-month FDA delay prompted a cash-strapped biotech company to shutter. The White House’s proposed NIH cuts are drawing bipartisan backlash. Peptide hype is outpacing evidence. And more!
The need-to-know this morning
Neurocrine Biosciences said this morning that it would buy Soleno Therapeutics and its treatment for Prader-Willi syndrome
Comments (0)